NCT05615636 2026-03-16A Phase II Trial of Mosunetuzumab, Polatuzumab, Tafasitamab, and Lenalidomide in Patients With Relapsed B-cell NHLM.D. Anderson Cancer CenterPhase 2 Recruiting36 enrolled
NCT04970901 2026-03-13A Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination With Other Anti-cancer Agents in Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (LOTIS-7)ADC Therapeutics S.A.Phase 1 Recruiting200 enrolled